Literature DB >> 19890901

FDG PET imaging of childhood sarcomas.

Rajen J Mody1, Chuong Bui, Raymond J Hutchinson, Greg A Yanik, Valerie P Castle, Kirk A Frey, Barry L Shulkin.   

Abstract

BACKGROUND: Positron-emission tomography (PET) imaging using [(18)F]fluorodeoxyglucose (FDG) is useful for detection, staging, and monitoring a variety of malignancies, including lymphoma, in adults, but its utility in sarcomas, especially soft tissue sarcomas (STS), in children and young adults is not clear. PROCEDURE: To evaluate the potential utility of FDG PET in the care of STS in children and young adults, we analyzed 46 PET scans in 25 patients acquired over 12 years. Scans were interpreted by two imaging physicians blinded to findings from other imaging studies and clinical information. Results were compared with computed tomography and magnetic resonance imaging, biopsy results, where available, and clinical follow-up of at least 12 months.
RESULTS: For a total of 46 scans in 25 patients, there were 25 true-positive scans, 3 false-positive scans, 12 true-negative scans, and 6 false-negative scans. The sensitivity of the PET scan was 86%, specificity was 80%, positive predictive value was 89%, and negative predictive value was 67%.
CONCLUSION: FDG PET may be a useful imaging modality in the management of children and young adults with STS, although prospective studies are needed to establish its true utility. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19890901      PMCID: PMC2794959          DOI: 10.1002/pbc.22307

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  22 in total

1.  SUV: standard uptake or silly useless value?

Authors:  J W Keyes
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

2.  Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas.

Authors:  B Plaat; A Kole; M Mastik; H Hoekstra; W Molenaar; W Vaalburg
Journal:  Eur J Nucl Med       Date:  1999-04

Review 3.  Whole-body FDG-PET imaging in the management of patients with cancer.

Authors:  Roland Hustinx; François Bénard; Abass Alavi
Journal:  Semin Nucl Med       Date:  2002-01       Impact factor: 4.446

4.  Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine.

Authors:  David C P Cobben; Philip H Elsinga; Albert J H Suurmeijer; Wim Vaalburg; Bram Maas; Piet L Jager; Harald J Hoekstra
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

5.  Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.

Authors:  B L Shulkin; D S Mitchell; D R Ungar; D Prakash; M G Dole; V P Castle; R J Hernandez; R A Koeppe; R J Hutchinson
Journal:  Radiology       Date:  1995-02       Impact factor: 11.105

6.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.

Authors:  Douglas S Hawkins; Joseph G Rajendran; Ernest U Conrad; James D Bruckner; Janet F Eary
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

7.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.

Authors:  D E Kuhl; S Minoshima; J A Fessler; K A Frey; N L Foster; E P Ficaro; D M Wieland; R A Koeppe
Journal:  Ann Neurol       Date:  1996-09       Impact factor: 10.422

8.  [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Authors:  J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-11       Impact factor: 9.236

9.  Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.

Authors:  Janet F Eary; Finbarr O'Sullivan; Yudi Powitan; Kingshuk Roy Chandhury; Cheryl Vernon; James D Bruckner; Ernest U Conrad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-19       Impact factor: 9.236

10.  The impact of PET scanning on management of paediatric oncology patients.

Authors:  E A Wegner; S F Barrington; J E Kingston; R O Robinson; R E Ferner; M Taj; M A Smith; M J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-31       Impact factor: 9.236

View more
  16 in total

Review 1.  Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.

Authors:  Giorgio Treglia; Marco Salsano; Antonella Stefanelli; Maria Vittoria Mattoli; Alessandro Giordano; Lorenzo Bonomo
Journal:  Skeletal Radiol       Date:  2011-11-10       Impact factor: 2.199

2.  Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.

Authors:  A Raciborska; K Bilska; K Drabko; E Michalak; R Chaber; M Pogorzała; K Połczyńska; G Sobol; M Wieczorek; K Muszyńska-Rosłan; M Rychlowska-Pruszyńska; C Rodriguez-Galindo; M Dziuk
Journal:  Clin Transl Oncol       Date:  2015-08-07       Impact factor: 3.405

Review 3.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

4.  Peripheral neuroectodermal tumour of the kidney (Ewing's sarcoma): Restaging with (18)F-fluorodeoxyglucose (FDG)-PET/CT.

Authors:  Hakan Ozturk
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

5.  Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.

Authors:  Caitlin Hurley; M Beth McCarville; Barry L Shulkin; Shenghua Mao; Jianrong Wu; Fariba Navid; Najat C Daw; Alberto S Pappo; Michael W Bishop
Journal:  Pediatr Blood Cancer       Date:  2016-04-15       Impact factor: 3.167

6.  Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas.

Authors:  Edit Bárdi; Mónika Csóka; Ildikó Garai; István Szegedi; Judit Müller; Tamás Györke; Kornélia Kajáry; Karolina Nemes; Csongor Kiss; Gábor Kovács
Journal:  Pathol Oncol Res       Date:  2013-08-17       Impact factor: 3.201

7.  Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma.

Authors:  Sara M Federico; Sheri L Spunt; Matthew J Krasin; Catherine A Billup; Jianrong Wu; Barry Shulkin; Gerald Mandell; M Beth McCarville
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology.

Authors:  Thomas Pfluger; Henriette I Melzer; Wolfgang P Mueller; Eva Coppenrath; Peter Bartenstein; Michael H Albert; Irene Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

9.  Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma.

Authors:  Punit Sharma; Bangkim Chandra Khangembam; K C Sudhir Suman; Harmandeep Singh; Sishir Rastogi; Shah Alam Khan; Sameer Bakhshi; Sanjay Thulkar; Chandrasekhar Bal; Arun Malhotra; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-05       Impact factor: 9.236

10.  The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients.

Authors:  Alaa Elmanzalawy; Reza Vali; Govind B Chavhan; Abha A Gupta; Yusuf Omarkhail; Afsaneh Amirabadi; Amer Shammas
Journal:  Pediatr Radiol       Date:  2019-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.